Recent Updates
Recently added Catalysts
BLRX Negative Sentiment Score: 15/100

BioLineRx Class Action Alert: Submit Your Losses to Johnson Fistel

Key Takeaway: A class action lawsuit has been filed against BioLineRx Ltd. on behalf of investors who purchased securities between February 23, 2021, and September 19, 2022. The lawsuit alleges that BioLineRx made misleading statements about its financial situation and the development of its drug, Motixafortide. Claims indicate that the company misrepresented its ability to fund development while also needing loans and additional securities offerings. Investors have until March 6, 2023, to apply to be the lead plaintiff in this case.

Market Sentiment Analysis

CONCERNS & RISKS

  • Ongoing class action lawsuit suggests serious legal challenges for BioLineRx.
  • Allegations of misleading statements regarding financial stability and pipeline development.
  • Potential financial impacts due to required loans for further development.

Full Press Release Details

SAN DIEGO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of BioLineRx Ltd. (NASDAQ: BLRX). The class action is on behalf of shareholders who purchased BioLineRx securities between February 23, 2021 and September 19, 2022, both dates inclusive (the “Class Period”). Investors are hereby notified that they have until March 6, 2023, to move the Court to serve as lead plaintiff in this action.
What actions may I take at this time? If you suffered a loss and are interested in learning more about being a lead plaintiff, please contact Jim Baker (jimb@johnsonfistel.com) by email or phone at 619-814-4471. If emailing, please include a phone number.
To join this action, you can click or copy and paste the link below into a browser:
There is no cost or obligation to you.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose, among other things, that: (1) the Company was not well financed to develop Motixafortide while at the same time advancing other pipeline programs; (2) BioLine would require a loan from Kreos Capital VII Aggregator SCSP in an aggregate principal amount of up to $40 million and then also would require a $15M securities offering to facilitate the commercial launch of Motixafortide; and (3) as a result of the foregoing, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the truth emerged, the lawsuit claims that investors suffered damages.
A lead plaintiff will act on behalf of all other class members in directing the BioLineRx class-action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class-action lawsuit. An investor's ability to share any potential future recovery of the BioLineRx class action lawsuit is not dependent upon serving as lead plaintiff.
For more information regarding the lead plaintiff process please refer to https://www.johnsonfistel.com/lead-plaintiff-deadlines.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. Johnson Fistel seeks to recover losses incurred due to violations of federal securities laws. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Jim Baker, 619-814-4471

Tags

Frequently Asked Questions

What is the class action lawsuit about BioLineRx?

The lawsuit involves shareholders who purchased BioLineRx securities between February 23, 2021, and September 19, 2022.

What is the deadline for becoming a lead plaintiff?

Investors have until March 6, 2023, to apply to serve as lead plaintiff in the lawsuit.

Who can I contact for more information?

You can contact Jim Baker via email at jimb@johnsonfistel.com or call 619-814-4471.

Are there any costs to join the class action?

There is no cost or obligation to join the BioLineRx class action lawsuit.

What were the misleading statements by BioLineRx?

The company allegedly misrepresented its financial readiness to advance Motixafortide and related programs.

Last updated: Jan 5, 2023